- Report
- January 2022
- 42 Pages
Global
From €3577EUR$3,750USD£3,046GBP
- Report
- September 2021
- 144 Pages
China
From €3816EUR$4,000USD£3,249GBP
- Report
- June 2021
- 197 Pages
Latin America
From €3816EUR$4,000USD£3,249GBP
- Report
- July 2020
- 300 Pages
Global
From €5247EUR$5,500USD£4,467GBP
- Report
- March 2019
- 168 Pages
Global
From €1312EUR$1,375USD£1,117GBP
€2623EUR$2,750USD£2,234GBP
- Report
- April 2018
- 159 Pages
Global
From €596EUR$625USD£508GBP
€1192EUR$1,250USD£1,015GBP
From €4293EUR$4,500USD£3,655GBP
- Report
- April 2024
- 80 Pages
Argentina
From €2476EUR$2,595USD£2,108GBP
- Report
- April 2024
- 80 Pages
Brazil
From €2476EUR$2,595USD£2,108GBP
- Report
- April 2024
- 80 Pages
France
From €2476EUR$2,595USD£2,108GBP
- Report
- April 2024
- 80 Pages
Germany
From €2476EUR$2,595USD£2,108GBP
- Report
- April 2024
- 80 Pages
Ireland
From €2476EUR$2,595USD£2,108GBP
- Report
- April 2024
- 80 Pages
Japan
From €2476EUR$2,595USD£2,108GBP
- Report
- April 2024
- 80 Pages
Poland
From €2476EUR$2,595USD£2,108GBP
- Report
- April 2024
- 80 Pages
Russia
From €2476EUR$2,595USD£2,108GBP
- Report
- April 2024
- 80 Pages
United Kingdom
From €2476EUR$2,595USD£2,108GBP
- Report
- April 2024
- 80 Pages
Vietnam
From €2476EUR$2,595USD£2,108GBP
- Report
- April 2024
- 80 Pages
China
From €2476EUR$2,595USD£2,108GBP
- Report
- April 2024
- 80 Pages
India
From €2476EUR$2,595USD£2,108GBP
- Report
- April 2024
- 80 Pages
Saudi Arabia
From €2476EUR$2,595USD£2,108GBP
The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more